{
    "elements": [
        {
            "type": "image",
            "sequence_num": 1,
            "data": {
                "url": "MEHTSOP046 Trial Closure 1.0.001.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 2,
            "data": {
                "num_rows": 15,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Title:"
                    },
                    {
                        "text": "RESEARCH & DEVELOPMENT TRIAL CLOSURE"
                    },
                    {
                        "text": "Document Reference/Register no:"
                    },
                    {
                        "text": "MEHTSOP046"
                    },
                    {
                        "text": "Version Number:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Document type: (Policy/ Guideline/ SOP)"
                    },
                    {
                        "text": "SOP"
                    },
                    {
                        "text": "To be followed by: (Target Staff)"
                    },
                    {
                        "text": "All staff"
                    },
                    {
                        "text": "Ratification Issue Date: (Date document is uploaded onto the intranet)"
                    },
                    {
                        "text": "th11 December 2019"
                    },
                    {
                        "text": "Review Date:"
                    },
                    {
                        "text": "th10 December 2022"
                    },
                    {
                        "text": "Developed in response to:"
                    },
                    {
                        "text": "Service Development"
                    },
                    {
                        "text": "Contributes to HSC Act 2008 (Regulated Activities) Regulations 2014(Part 3); and CQC Regulations 2009 (Part 4) CQC Fundamental Standards of Quality and Safety:"
                    },
                    {
                        "text": "17"
                    },
                    {
                        "text": "Issuing Division/Directorate:"
                    },
                    {
                        "text": "Research & Development"
                    },
                    {
                        "text": "Author/Contact: (Asset Administrator)"
                    },
                    {
                        "text": "Lauren Perkins, R & D Manager"
                    },
                    {
                        "text": "Hospital Sites: (tick appropriate box/es to indicate status of policy review i.e. joint/ independent)"
                    },
                    {
                        "text": "\uf0fcMEHT \u25a1 BTUH \u25a1 SUH"
                    },
                    {
                        "text": "Consultation:"
                    },
                    {
                        "text": "(Refer to page 2)"
                    },
                    {
                        "text": "Approval Group / Committee(s):"
                    },
                    {
                        "text": "Research and Development"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "04/07/2019"
                    },
                    {
                        "text": "Professionally Approved by: (Asset Owner)"
                    },
                    {
                        "text": "Tracey Camburn R & D Director, Clinical Lead Nurse"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "26/07/2019"
                    },
                    {
                        "text": "Ratification Group(s):"
                    },
                    {
                        "text": "DRAG Chair's Action"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "11th December 2019"
                    },
                    {
                        "text": "Executive and Clinical Directors (Communication of minutes from Document Ratification Group"
                    },
                    {
                        "text": "Date: December 2019"
                    },
                    {
                        "text": "Distribution Method:"
                    },
                    {
                        "text": "Intranet & Website"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 3,
            "data": {
                "url": "MEHTSOP046 Trial Closure 1.0.002.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 4,
            "data": {
                "num_rows": 13,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Consulted With:"
                    },
                    {
                        "text": "Post/ Approval Committee/ Group:"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "Lucy Willsher"
                    },
                    {
                        "text": "Oncology research nurse"
                    },
                    {
                        "text": "02/07/2019 04/07/2019"
                    },
                    {
                        "text": "Beth Farr"
                    },
                    {
                        "text": "Clinical Research Set Up"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 5,
            "data": {
                "num_rows": 1,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Related Trust Policies (to be read in conjunction with)"
                    },
                    {
                        "text": "SOP-07- Role of CI, pharmacy, nuclear medicine and R&D MEHTSOP061 Research Staff Training MEHTSOP059 Amendments MEHTSOP054 Writing Research Protocols MEHTSOP050 Archiving SOP-21- End of Study Reports"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 6,
            "data": {
                "num_rows": 10,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Review History:"
                    },
                    {
                        "text": "Version No:"
                    },
                    {
                        "text": "Authored/Reviewer:"
                    },
                    {
                        "text": "Summary of amendments/ Record documents superseded by:"
                    },
                    {
                        "text": "Issue Date:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Lauren Perkins"
                    },
                    {
                        "text": "Newly created"
                    },
                    {
                        "text": "11th December 2019"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 7,
            "data": {
                "is_heading": 1,
                "text": "Contents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 8,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Background"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 9,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Purpose"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 10,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Applicable to"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 11,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Responsibilities"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 12,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Procedure"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 13,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Equality Impact Assessment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 14,
            "data": {
                "is_heading": 0,
                "text": "Appendix 1.0 - Definitions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 15,
            "data": {
                "is_heading": 0,
                "text": "Appendix 2.0 \u2013 Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 16,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "BACKGROUND"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 17,
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "This documents sets out the procedures to be followed by all staff who are involved in the close-down, termination, suspension or final reporting of research studies and clinical trials."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 18,
            "data": {
                "is_heading": 0,
                "prefix": 1.2,
                "text": "It provides guidance on how patients, staff and trial related documentation is managed during close-out so as to ensure compliance with the Trust's Information Governance Policies, the Data Protection Act (2000), and other relevant legislation and policy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 19,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "PURPOSE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 20,
            "data": {
                "is_heading": 0,
                "prefix": 2.1,
                "text": "To ensure all Mid Essex Hospital Services NHS Trust (MEHT) sponsored and hosted trials are closed according to protocol, regulatory and sponsor requirements."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 21,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "APPLICABLE TO"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 22,
            "data": {
                "is_heading": 0,
                "prefix": 3.1,
                "text": "Any Trust employee (including those with an honorary research contract or letter of access) involved with clinical research including, Chief Investigators (CI), Principal Investigators (PI), Consultants, Clinical Trial Pharmacists, Research Managers, Statisticians, Research Nurses, Research Midwives, Allied Health Professionals, Trial Coordinators, Data Managers & R&D Administrative Staff."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 23,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "RESPONSIBILITIES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 24,
            "data": {
                "is_heading": 0,
                "prefix": 4.1,
                "text": "The Chief Investigator/Principal Investigator or delegate is responsible for the closure of the trial according to regulatory and sponsor requirements (gSOP-07). The Chief Investigator and delegate should ensure for MEHT sponsored trials that the end of trial is detailed in the approved protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 25,
            "data": {
                "is_heading": 0,
                "prefix": 4.2,
                "text": "For MEHT sponsored CTIMP trials, the R&D office as the sponsor's representative will ensure that the approved protocol provides adequate detail regarding end of trial (gSOP-13) and R&D Office will ensure that these trials are closed according to the protocol, regulatory and Trust requirements."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 26,
            "data": {
                "is_heading": 0,
                "prefix": 4.3,
                "text": "The definition of the end of study should be agreed before the study start and documented clearly in both the protocol and any corresponding agreements. If the definition of the end of trial is amended during the course of the trial this should be submitted as a substantial amendment (gSOP-08)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 27,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "PROCEDURES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 28,
            "data": {
                "is_heading": 1,
                "prefix": 5.1,
                "text": "Closure to Recruitment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 29,
            "data": {
                "is_heading": 1,
                "text": "5.1.1 Trial Closed to Recruitment: When a trial has recruited its target number of patients as detailed in the protocol. If the trial is multicentre this must mean that no further patients can be recruited at any of the participating sites, however, patients may still be on treatment when the trial is closed to recruitment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 30,
            "data": {
                "is_heading": 0,
                "text": "5.1.2 Once a trial has completed recruitment, but patients are still on treatment the CI/PI or delegate should complete the Trial Status notification form and submit it to R&D."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 31,
            "data": {
                "is_heading": 0,
                "text": "5.1.3 R&D will acknowledge the change in status and update the R&D database."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 32,
            "data": {
                "is_heading": 0,
                "text": "5.1.4 For MEHT sponsored multicentre studies it is important to ensure that the end to recruitment is clearly communicated and subsequently documented at each site. It is the PI's responsibility to ensure that the participating site's R&D office is informed about the change in status and that evidence of this is kept in the Investigator Site File (ISF). The Trial Master File (TMF) should also contain documentation to show that each site was informed of the trial's closure to recruitment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 33,
            "data": {
                "is_heading": 0,
                "prefix": 5.3,
                "text": "5.1.5 Once the trial is ready to close as defined in the protocol or the research team should start close out procedures as detailed in sections 5.2,  or 5.4 depending on the type of study."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 34,
            "data": {
                "is_heading": 1,
                "prefix": 5.2,
                "text": "Externally Sponsored (commercial and non-commercial) MEHT Hosted Trial Closure Procedures"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 35,
            "data": {
                "is_heading": 1,
                "text": "5.2.1 Regulatory End of Trial: The end of trial should be detailed in the protocol, but where this is not the case the trial should be closed 30 days after the last patient has received their last treatment including any patients at multicentre sites."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 36,
            "data": {
                "is_heading": 0,
                "text": "5.2.2 The Research team should send a copy of the formal notification of study closure received from the sponsor to the R&D office."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 37,
            "data": {
                "is_heading": 0,
                "text": "5.2.3 The Sponsor will liaise with the Trust pharmacy to ensure that they are closed in accordance with regulatory and protocol requirements."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 38,
            "data": {
                "is_heading": 0,
                "text": "5.2.4 Once R&D has received the Sponsor's notification of study closure they will close the study on the R&D database."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 39,
            "data": {
                "is_heading": 0,
                "text": "5.2.5 If MEHT has accepted responsibility for trial closure then certain sections below may be applicable depending on the type of trial."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 40,
            "data": {
                "is_heading": 0,
                "text": "5.2.6 Flow Diagram: Trial Closure Procedure for Hosted Studies"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 41,
            "data": {
                "is_heading": 0,
                "text": "Sponsor to send formal notification of trial closure to the Research Team"
            }
        },
        {
            "type": "image",
            "sequence_num": 42,
            "data": {
                "url": "MEHTSOP046 Trial Closure 1.0.003.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 43,
            "data": {
                "is_heading": 0,
                "text": "Research Team to send formal notification of  Sponsor to liaise with Pharmacy to close trial closure from the Sponsor to R&D down study in accordance with"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 44,
            "data": {
                "is_heading": 0,
                "text": "protocol/regulatory requirements"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 45,
            "data": {
                "is_heading": 0,
                "text": "Upon receipt of the Trial Status change R&D to update the R&D database"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 46,
            "data": {
                "is_heading": 0,
                "text": "Research Team to file letter in Investigator Site File"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 47,
            "data": {
                "is_heading": 1,
                "prefix": 5.3,
                "text": "MEHT Sponsored CTIMP Trial Closure Procedures"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 48,
            "data": {
                "is_heading": 0,
                "text": "5.3.1 Where studies have closed before the expected date of closure a letter should be sent by the CI or delegate to the RDSG informing of the reasons before the End of Trial Notification form is submitted to the regulatory authorities. The date of this letter will then determine the deadline for the End of Trial Report as detailed in gSOP-22."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 49,
            "data": {
                "is_heading": 0,
                "text": "5.3.2 The CI or delegate should inform the R&D Office of the intention to close the study."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 50,
            "data": {
                "is_heading": 0,
                "text": "5.3.3 For multicentre studies evidence must be available in the TMF that all of the sites are ready to close out."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 51,
            "data": {
                "is_heading": 0,
                "text": "5.3.4 CI/PI or delegate should liaise with pharmacy to ensure accountability is performed and  excess  IMP  is  returned  or  destroyed  as  detailed  in  the  protocol,  legal requirements and relevant pharmacy SOPs. Drug accountability logs and records of returns or destruction should be filed in the TMF/ISF."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 52,
            "data": {
                "is_heading": 0,
                "text": "5.3.5 The Trial Co-ordinator will ensure that the TMF and Pharmacy files are up-to-date and will then inform the team that they have permission to close the trial as detailed in section 5.2."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 53,
            "data": {
                "is_heading": 0,
                "text": "5.3.6 Once the R&D Office has given permission the CI/PI or delegate should complete the End of Trial Notification form."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 54,
            "data": {
                "is_heading": 0,
                "text": "5.3.7 For multicentre studies the End of Trial Notification form should be submitted when the trial has ended at all of the sites."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 55,
            "data": {
                "is_heading": 0,
                "text": "5.3.8 The End of Trial Notification form must be sent to the Medicines and Healthcare Products Regulatory Agency (MHRA), main Research Ethics Committee (REC) and R&D office within 90 days of the trial ending."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 56,
            "data": {
                "is_heading": 0,
                "text": "5.3.9 For trials that are terminated early the MHRA, main REC, and R&D should be informed within 15 days and the CI/PI should clearly explain the reasons for the early termination."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 57,
            "data": {
                "is_heading": 0,
                "text": "5.3.10 If the trial did not start the CI/PI must notify the MHRA, main REC and R&D and provide an explanation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 58,
            "data": {
                "is_heading": 0,
                "text": "5.3.11 The CI/PI or delegate must ensure that the ISF/TMF is kept up-to-date with all End of Trial Notification forms and final reports."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 59,
            "data": {
                "is_heading": 0,
                "text": "5.3.12 Once R&D has received the End of Trial Notification form they will close the study on the R&D database. Once the study has been closed the R&D office will request any outstanding annual progress reports before sending to the research team."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 60,
            "data": {
                "is_heading": 0,
                "text": "5.3.13 The R&D team will also forward a copy of the End of Trial Notification form and the R&D acknowledgement letter to Pharmacy for their records."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 61,
            "data": {
                "is_heading": 0,
                "text": "5.3.14 Once the End of Trial acknowledgements have been received from the MHRA, main REC and R&D the study can be considered closed and can be archived following the standard operating procedure for archiving gSOP-16."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 62,
            "data": {
                "is_heading": 0,
                "text": "5.3.15 The CI/PI should change the status on clinicaltrials.gov"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 63,
            "data": {
                "is_heading": 0,
                "text": "5.3.16 End of study reports should be submitted within 1 year of study closure (gSOP-21)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 64,
            "data": {
                "is_heading": 0,
                "text": "5.3.17 Please refer to the sponsored trial closure procedure for a flow diagram of the process (Appendix 2)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 65,
            "data": {
                "is_heading": 1,
                "prefix": 5.4,
                "text": "MEHT Sponsored Non-CTIMP Trial Closure Procedures"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 66,
            "data": {
                "is_heading": 0,
                "text": "5.4.1 For multicentre studies evidence must be available in the TMF that all of the sites are closed to recruitment and are ready to close out."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 67,
            "data": {
                "is_heading": 0,
                "text": "5.4.2 The CI/PI should complete the Declaration of End of Study."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 68,
            "data": {
                "is_heading": 0,
                "text": "5.4.3 For multicentre studies the Declaration of End of Study should be submitted when the trial has ended at all of the sites."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 69,
            "data": {
                "is_heading": 0,
                "text": "5.4.4 The Declaration of End of Study must be sent to the main REC and R&D within 90 days of the trial ending. CI/PI update clinicaltrials.gov status"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 70,
            "data": {
                "is_heading": 0,
                "prefix": 15.0,
                "text": "5.4.5 For trials that are terminated early the main REC, and R&D should be informed within  days and the CI/PI should clearly explain the reasons for the early termination."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 71,
            "data": {
                "is_heading": 0,
                "text": "5.4.6 If the trial did not start the CI/PI must notify the main REC and R&D and provide an explanation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 72,
            "data": {
                "is_heading": 0,
                "text": "5.4.7 The CI/PI or delegate must ensure that the ISF/TMF is kept up-to-date with all Declaration of End of Study forms and final reports."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 73,
            "data": {
                "is_heading": 0,
                "text": "5.4.8 Once R&D has received the Declaration of End of Study form they will close the study on the R&D database."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 74,
            "data": {
                "is_heading": 0,
                "text": "5.4.9 The R&D team will also forward a copy of the Declaration of End of Study form and the R&D acknowledgement letter to Pharmacy (if required) for their records."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 75,
            "data": {
                "is_heading": 0,
                "text": "5.4.10 Once the End of Trial acknowledgements have been received from the main REC and R&D the study can be considered closed and can be archived following the standard operating procedure for archiving gSOP-16."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 76,
            "data": {
                "is_heading": 0,
                "text": "5.4.11 End of study reports should be submitted within 1 year of study closure (gSOP-21)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 77,
            "data": {
                "is_heading": 0,
                "text": "5.4.12 Please refer to the sponsored trial closure procedure for a flow diagram of the process (Appendix 2)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 78,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "EQUALITY IMPACT ASSESSMENT"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 79,
            "data": {
                "is_heading": 0,
                "prefix": 7.1,
                "text": "Mid Essex Hospital Services NHS Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals. (Refer to Appendix 3)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 80,
            "data": {
                "is_heading": 1,
                "text": "Appendix 1: Definitions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 81,
            "data": {
                "is_heading": 1,
                "text": "Chief Investigator (CI) -  The person who takes overall responsibility for the design, conduct and reporting of a study if it is at one site; or if the study involves researchers at more than one site, the person who takes primary responsibility for the design conduct and reporting of the study whether or not that person is an Investigator at any particular site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 82,
            "data": {
                "is_heading": 1,
                "text": "Clinical Trial - Any investigation in human subjects, other than a non-interventional trial intended to discover or verify the clinical, pharmacological or other pharmacodynamic effects of one or more medicinal product or to identify any adverse reactions to one or more such products and to study absorption, distribution metabolism and excretion in one of more such products with the object of ascertaining the safety or efficacy of those products."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 83,
            "data": {
                "is_heading": 1,
                "text": "Clinical Trial of an Investigational Medicinal Product (CTIMP) - This is defined as any Clinical Research Study which intends to generate new information about the safety or efficacy of a Medicinal Product."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 84,
            "data": {
                "is_heading": 1,
                "text": "Closedown - Closedown is the process that occurs at study conclusion. This consists of notification of study conclusion to relevant competent authority(ies), final report completion and maintenance and archiving of essential documents."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 85,
            "data": {
                "is_heading": 1,
                "text": "Honorary Research Contract (HRC) - HRCs are required for researchers who are not employees of the NHS and whose activities could have a foreseeable and direct impact on patient care."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 86,
            "data": {
                "is_heading": 1,
                "text": "Investigational Medicinal Products (IMP) - means a pharmaceutical form of an active substance or placebo being tested, or used as a reference in a clinical trial. This includes a medicinal product which has a marketing authorisation but is, for the purposes of the trial -"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 87,
            "data": {
                "is_heading": 0,
                "text": "(a) used or assembled (formulated or packaged) in a way different from the form of the product authorised under the authorisation,"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 88,
            "data": {
                "is_heading": 0,
                "text": "(b) used for an indication not included in the summary of product characteristics under the authorisation for that product, or"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 89,
            "data": {
                "is_heading": 0,
                "text": "(c) used to gain further information about the form of that product as authorised under the authorisation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 90,
            "data": {
                "is_heading": 1,
                "text": "Letter of Access - Letters of access enable NHS employees or staff with an honorary clinical contract (e.g. clinical academics) with one NHS organisation to conduct research in another NHS organisation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 91,
            "data": {
                "is_heading": 1,
                "text": "Principal Investigator (PI) - The leader responsible for a team of individuals conducting a study at a (participating) site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 92,
            "data": {
                "is_heading": 1,
                "text": "The Medicines & Healthcare products Regulatory Agency (MHRA) - The government agency which is responsible for ensuring that medicines and medical devices work, and are acceptably safe1."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 93,
            "data": {
                "is_heading": 0,
                "text": "The MHRA can also be defined as:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 94,
            "data": {
                "is_heading": 0,
                "text": "MHRA (Medicines) is the competent authority for the UK in relation to the EU Directive and the Clinical Trials Regulations. MHRA (Devices) is the competent authority for the UK in relation to the Medical Devices Regulations 2002."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 95,
            "data": {
                "is_heading": 1,
                "prefix": 2004.0,
                "text": "The Regulations - Medicines for Human Use (Clinical Trial) Regulations 2004 transposed the EU Clinical Trials Directive into UK legislation, as Statutory Instrument 2004 no 1031. This became effective on the 1st May  An amendment to implement Directive 2005/28/EC was made to the Regulations as Statutory Instrument 2006 no 1928."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 96,
            "data": {
                "is_heading": 1,
                "text": "Regulatory End of Trial: The end of trial should be detailed in the protocol, but where this is not the case the trial should be closed 30 days after the last patient has received their last treatment/visit including any patients at multicentre sites."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 97,
            "data": {
                "is_heading": 1,
                "text": "Trial Closed to Recruitment - When a trial has recruited its target number of patients as detailed in the protocol. If the trial is multicentre this must mean that no further patients can be recruited at any of the participating sites, however, patients may still be on treatment when the trial is closed to recruitment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 98,
            "data": {
                "is_heading": 1,
                "text": "Appendix 2: MEHT Sponsored Trial Closure Procedure Flow diagram"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 99,
            "data": {
                "is_heading": 0,
                "text": "Is study CTIMP or Non-CTIMP?"
            }
        },
        {
            "type": "image",
            "sequence_num": 100,
            "data": {
                "url": "MEHTSOP046 Trial Closure 1.0.004.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 101,
            "data": {
                "is_heading": 0,
                "text": "CTIMP Non-CTIMP"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 102,
            "data": {
                "is_heading": 0,
                "text": "Contact R&D to arrange close out visit"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 103,
            "data": {
                "is_heading": 0,
                "text": "Close out visit. Once all issues are resolved following the close out visit the R&D Office will permit formal closure of the trial"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 104,
            "data": {
                "is_heading": 0,
                "text": "CI or delegate completes End of Trial  CI/PI completes Declaration of End of Notification form and sends to MHRA,  Study and sends to REC and R&D within"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 105,
            "data": {
                "is_heading": 0,
                "text": "REC and R&D within 90 days or 15 days if  90 days or 15 days if terminated early. terminated early. Update clinicaltrials.gov Update clinicaltrials.gov"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 106,
            "data": {
                "is_heading": 0,
                "text": "Pharmacy sent a"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 107,
            "data": {
                "is_heading": 0,
                "text": "copy of end of trial  Receive End of Trial notification and  Acknowledgement letters"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 108,
            "data": {
                "is_heading": 0,
                "text": "R&D"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 109,
            "data": {
                "is_heading": 0,
                "text": "acknowledgement"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 110,
            "data": {
                "is_heading": 0,
                "text": "Study Reports within 12 months of completion. Send a copy to MHRA (if appropriate), REC and R&D."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 111,
            "data": {
                "is_heading": 0,
                "text": "Database analysis after database lock Dissemination of results"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 112,
            "data": {
                "is_heading": 0,
                "text": "Archiving (gSOP-17)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 113,
            "data": {
                "is_heading": 0,
                "text": "Research & Development Trial Closure/ MEHTSOP046/1.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 114,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 115,
            "data": {
                "is_heading": 1,
                "text": "Appendix 3: Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 116,
            "data": {
                "is_heading": 1,
                "text": "This assessment relates to: Research & Development Trial Closure/ MEHTSOP046"
            }
        },
        {
            "type": "table",
            "sequence_num": 117,
            "data": {
                "num_rows": 9,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "A change in a service to patients"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to an existing policy"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to the way staff work"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A new policy"
                    },
                    {
                        "text": "X"
                    },
                    {
                        "text": "Something else (please give details)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Questions"
                    },
                    {
                        "text": "Answers"
                    },
                    {
                        "text": "What are you proposing to change?"
                    },
                    {
                        "text": "New SOP"
                    },
                    {
                        "text": "Why are you making this change? (What will the change achieve?)"
                    },
                    {
                        "text": "Review"
                    },
                    {
                        "text": "Who benefits from this change and how?"
                    },
                    {
                        "text": "Patients and clinicians"
                    },
                    {
                        "text": "Is anyone likely to suffer any negative impact as a result of this change? If no, please record reasons here and sign and date this assessment. If yes, please complete a full EIA."
                    },
                    {
                        "text": "No"
                    },
                    {
                        "text": "a) Will you be undertaking any consultation as part of this change? b) If so, with whom?"
                    },
                    {
                        "text": "Refer to pages 1 and 2"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 118,
            "data": {
                "is_heading": 1,
                "text": "Preliminary analysis completed by:"
            }
        },
        {
            "type": "table",
            "sequence_num": 119,
            "data": {
                "num_rows": 1,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Name"
                    },
                    {
                        "text": "Lauren Perkins"
                    },
                    {
                        "text": "Job Title"
                    },
                    {
                        "text": "Research & Development Manager"
                    },
                    {
                        "text": "Date"
                    },
                    {
                        "text": "July 2019"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 120,
            "data": {
                "is_heading": 0,
                "text": "Research & Development Trial Closure/ MEHTSOP046/1.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 121,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        }
    ]
}